Delaware
|
333-88480
|
#90-0577933
|
||
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
489 5th Ave, 28th Floor, New York, NY
|
10017
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
·
|
The term of the Warrants has been extended by one year to October 31, 2012 (“Extension Period”).
|
·
|
Early termination: In the event that the market price of the Company’s Common Stock shall exceed $1.50 for five consecutive trading days, the Company at its option shall have the right to terminate the Extension Period with 10 business days notice to the warrant holder.
|
·
|
No cashless exercise: Section 4(b) of the Warrant Agreement, which provided for exercise of the Warrants by surrender of shares of Common Stock or Warrants, has been removed in its entirety during the Extension Period.
|
Exhibit No. | Description | |
10.22 | Form of Warrant Agreement, dated October 31, 2006 | |
10.23 | Amendment No. 1 to Warrant Agreement, dated October 31, 2011 |
OHR PHARMACEUTICAL, INC.
|
||
Dated: November 2, 2011 | ||
By: /s/ Irach Taraporewala | ||
Dr. Irach Taraporewala, President and CEO
|